Drug lookup | Fillwise

NITROGLYCERIN

All products: general benefit

Other products in the same Health Canada class (C01D, C01DA) — coverage varies; not interchangeable

Isosorbide dinitrate (Isdn): general benefit, Not a benefit
Isosorbide + mononitrate (Imdur): not a benefit
Vericiguat (Verquvo): limited Use 685

Transderm-Nitro · DIN 02046156 · 0.6mg/Hr/30 Sq Cm · Patch

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-05 — choose a marketed DIN from the same-category list.Discontinued 2022-04-05 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-05 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-05 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Transderm-Nitro · DIN 02046156 Manufacturer: Novartis Pharma Canada Inc.; listing date 1997-04-10 Health Canada: Cancelled post market since 2022-04-05 · brand TRANSDERM-NITRO 0.6 · ATC C01DA02 GLYCERYL TRINITRATE · form Patch (extended-release) · route Transdermal · ingredients NITROGLYCERIN 0.6 MG/HOUR · company Novartis pharmaceuticals canada inc · schedule Ethical

Check this DIN again · Health Canada product record

Transderm-Nitro: Formulary list price $1.0290/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0290 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15572 · Verify on the e-Formulary ↗ (DIN 02046156)

Source record

DIN 02046156: Transderm-Nitro Raw flags: sec3=Y Item: 241200059; group id 369; item number 0861; lccId None; manufacturer id NOV Source form: Patch; strength: 0.6mg/Hr/30 Sq Cm Recorded listing: General benefit Source prices (unrounded): $1.0290; ministry $1.0290 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02046156 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15572

Shortage status: discontinued (2021-09-02, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02046156

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2022-04-05 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered

Matched class: 24:12 Vasodilating Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ISOSORBIDE DINITRATE 24:12 Vasodilating Drugs

ISOSORBIDE DINITRATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 5mg, 10mg, 30mg · SL Tab, Tab

ISOSORBIDE-5-MONONITRATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 60mg · ER Tab

VERICIGUAT

· 3 products · Limited Use, codes 685 · strengths: 2.5mg, 5mg, 10mg · Tab

DIPYRIDAMOLE & ACETYLSALICYLIC ACID

· 2 products · Listed, not a benefit (1), Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap

NIMODIPINE

· 1 products · Limited Use, codes 42, 43 · strengths: 30mg · Tab

AMBRISENTAN

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab

BETAHISTINE DIHYDROCHLORIDE

· 24 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8mg, 16mg, 24mg · Tab

BOSENTAN MONOHYDRATE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab

DIPYRIDAMOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab

RIOCIGUAT

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab

TADALAFIL

· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

VARDENAFIL HCL

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:12

Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE NITROSTAT (nitroglycerin sublingual tablets) are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. https://pdf.hres.ca/dpd_pm/00070110.PDF PM date: March 27, 2023 Source product: NITROSTAT; DIN 00037613; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Transderm-Nitro · DIN 02046156 Shortage status: discontinued (2021-09-02, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02046156

Check this DIN again